Luci indicated the company is focused on securing additional funding opportunities to support the Phase 3 ibezapolstat clinical trial program and expects further updates on funding initiatives in ...
Xenon Pharmaceuticals provided an update on its pipeline programs, highlighting significant progress and upcoming milestones for 2025. The company anticipates topline data from its first Phase 3 study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback